A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
68actual
Sites
77
Countries
Argentina, Canada, Chile +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-12 | actual | When the study began enrolling |
| Primary completion | 2026-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colitis Ulcerative
Interventions
- Drug: Dupilumab — also filed as Dupixent
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants achieving clinical response at Week 24
measured Week 24
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed